Integra LifeSciences (NASDAQ:IART) received a $58.00 price target from equities research analysts at Oppenheimer in a research report issued on Tuesday. The brokerage currently has a “buy” rating on the life sciences company’s stock. Oppenheimer’s price objective would suggest a potential upside of 18.78% from the company’s current price.
A number of other research analysts have also recently commented on the company. Royal Bank of Canada restated a “sector perform” rating and issued a $50.00 price target (up previously from $48.00) on shares of Integra LifeSciences in a research report on Thursday, November 9th. UBS restated a “buy” rating and issued a $57.00 price target on shares of Integra LifeSciences in a research report on Tuesday, October 31st. Wells Fargo & Company cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Sunday, October 29th. Jefferies Group reiterated a “buy” rating and issued a $56.00 target price on shares of Integra LifeSciences in a research report on Sunday, October 29th. Finally, TheStreet cut Integra LifeSciences from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Integra LifeSciences currently has a consensus rating of “Buy” and an average price target of $53.64.
Integra LifeSciences (NASDAQ:IART) traded down $0.09 during mid-day trading on Tuesday, reaching $48.83. The company’s stock had a trading volume of 639,000 shares, compared to its average volume of 593,605. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The company has a market cap of $3,839.12, a PE ratio of 27.03, a price-to-earnings-growth ratio of 2.15 and a beta of 0.65. Integra LifeSciences has a 1 year low of $39.65 and a 1 year high of $56.42.
In other news, Director Barbara B. Hill purchased 10,768 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were purchased at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the purchase, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP lifted its stake in shares of Integra LifeSciences by 213.1% in the third quarter. GSA Capital Partners LLP now owns 28,249 shares of the life sciences company’s stock worth $1,426,000 after acquiring an additional 19,226 shares during the period. California Public Employees Retirement System lifted its stake in shares of Integra LifeSciences by 6.8% in the third quarter. California Public Employees Retirement System now owns 132,002 shares of the life sciences company’s stock worth $6,663,000 after acquiring an additional 8,402 shares during the period. Zions Bancorporation acquired a new position in shares of Integra LifeSciences in the third quarter worth approximately $205,000. Orbimed Advisors LLC lifted its stake in shares of Integra LifeSciences by 155.5% in the third quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after acquiring an additional 664,000 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its stake in shares of Integra LifeSciences by 20.9% in the third quarter. Segall Bryant & Hamill LLC now owns 112,520 shares of the life sciences company’s stock worth $5,680,000 after acquiring an additional 19,486 shares during the period. 87.62% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Oppenheimer Analysts Give Integra LifeSciences (IART) a $58.00 Price Target” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/oppenheimer-analysts-give-integra-lifesciences-iart-a-58-00-price-target.html.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.